Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96LJ7

UPID:
DHRS1_HUMAN

ALTERNATIVE NAMES:
Short chain dehydrogenase/reductase family 19C member 1

ALTERNATIVE UPACC:
Q96LJ7; D3DS71; Q8NDG3; Q96B59; Q96CQ5

BACKGROUND:
The enzyme Dehydrogenase/reductase SDR family member 1, recognized alternatively as Short chain dehydrogenase/reductase family 19C member 1, plays a critical role in the body's chemical processes. It is an NADPH-dependent oxidoreductase that catalyzes the reduction of a broad spectrum of substrates, including key steroids and xenobiotics. This activity is crucial for maintaining hormonal equilibrium and detoxifying various foreign agents, highlighting the enzyme's significance in metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dehydrogenase/reductase SDR family member 1 offers a promising avenue for developing novel therapeutic approaches. Given its central role in metabolizing steroids and xenobiotics, targeting this enzyme could lead to innovative treatments for disorders related to hormonal imbalances and toxicity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.